All In Biotech

Drug Trial Radar · NCT03935217

A Phase 3 Study of Solosec® for the Treatment of Trichomoniasis

Multi-center, Prospective, Randomized, Placebo-Controlled, Delayed Treatment, Double-Blind Study to Evaluate the Effectiveness and Safety of a Single Oral Dose of Solosec® for the Treatment of Trichomoniasis

Last checked: Nov 20, 2026Latest source record: Oct 4, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 147 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

147

Actual

Start

Apr 23, 2019

Primary completion

Mar 2, 2020

Study completion Mar 25, 2020

Sponsor

Lead sponsor
Lupin Research IncIndustry
Sponsor type
Industry
First posted
May 2, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, multi-center, prospective, randomized, placebo-controlled, delayed treatment, double-blind, study to evaluate the effectiveness, and safety of a single, oral dose of Solosec® containing 2 grams of secnidazole in female patients with trichomoniasis.

Conditions

  • Trichomonas Infection

Interventions

  • SecnidazoleDrug

    Oral Granules containing secnidazole

  • PlaceboDrug

    Oral Granules of placebo manufactured to mimic secnidazole

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Microbiological Cure at the TOC VisitTime frame: Study Day 6-12

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Site 1007

    Birmingham, Alabama

  • Site 1003

    North Miami, Florida

  • Site 1014

    Chicago, Illinois

  • Site 1013

    Jackson, Mississippi

  • Site 1009

    Lawrenceville, New Jersey

  • Site 1008

    Chapel Hill, North Carolina

  • Site 1004

    Fayetteville, North Carolina

  • Site 1011

    Charleston, South Carolina

  • Site 1001

    Memphis, Tennessee

  • Site 1002

    Memphis, Tennessee

  • Site 1006

    Virginia Beach, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.